Cancer-related outcomes in kidney allograft recipients in England versus New York State: a comparative population-cohort analysis between 2003 and 2013 by Jackson-spence, Francesca et al.
 
 
University of Birmingham
Cancer-related outcomes in kidney allograft
recipients in England versus New York State: a
comparative population-cohort analysis between
2003 and 2013
Jackson-spence, Francesca; Gillott, Holly; Tahir, Sanna; Nath, Jay; Mytton, Jemma; Evison,
Felicity; Sharif, Adnan
DOI:
10.1002/cam4.1015
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Jackson-spence, F, Gillott, H, Tahir, S, Nath, J, Mytton, J, Evison, F & Sharif, A 2017, 'Cancer-related outcomes
in kidney allograft recipients in England versus New York State: a comparative population-cohort analysis
between 2003 and 2013', Cancer Medicine, vol. 6, no. 3, pp. 563–571. https://doi.org/10.1002/cam4.1015
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
1Introduction
The need for lifelong immunosuppression to prevent rejec-
tion of the kidney allograft is associated with significant 
complications for patients after kidney transplantation [1]. 
Perhaps of greatest significance in the contemporary era 
of immunosuppression is the development of cancer [2], 
which is increasingly recognized as one of the primary 
causes of mortality post kidney transplantation [3–5] and 
one of the leading causes of concern from a patients’ 
perspective [6]. Therefore, efforts to increase our 
understanding of cancer- related epidemiology after kidney 
transplantation should be actively encouraged to aid 
transplant- specific clinical management and patient 
counseling.
However, our understanding of cancer incidence post 
kidney transplantation is limited to a small selection of 
population- cohort analyses specific to North America, 
Australia/New Zealand or the United Kingdom [7–11]. 
Transplant clinicians frequently rely on data published 
from population- cohort studies conducted in one country 
and translate directly to another. However, cancer- related 
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Abstract
It is unclear whether cancer- related epidemiology after kidney transplantation 
is translatable between countries. In this population- cohort study, we compared 
cancer incidence and all- cause mortality after extracting data for every kidney- 
alone transplant procedure performed in England and New York State (NYS) 
between 2003 and 2013. Data were analyzed for 18,493 and 11,602 adult re-
cipients from England and NYS respectively, with median follow up 6.3 years 
and 5.5 years respectively (up to December 2014). English patients were more 
likely to have previous cancer at time of transplantation compared to NYS 
patients (5.6% vs. 3.5%, P < 0.001). Kidney allograft recipients in England 
versus NYS had increased cancer incidence (12.3% vs. 5.9%, P < 0.001) but 
lower all- cause mortality during the immediate postoperative stay (0.7% vs. 
1.0%, P = 0.011), after 30- days (0.9% vs. 1.8%, P < 0.001) and after 1- year 
post- transplantation (3.0% vs. 5.1%, P < 0.001). However, mortality rates among 
patients developing post- transplant cancer were equivalent between the two 
countries. During the first year of follow up, if patients had an admission with 
a cancer diagnosis, they were more likely to die in both England (Odds Ratio 
4.28 [95% CI: 3.09–5.93], P < 0.001) and NYS (Odds Ratio 2.88 [95% CI: 
1.70–4.89], P < 0.001). Kidney allograft recipients in NYS demonstrated higher 
hazard ratios for developing kidney transplant rejection/failure compared to 
England on Cox regression analysis. Our analysis demonstrates significant dif-
ferences in cancer- related epidemiology between kidney allograft recipients in 
England versus NYS, suggesting caution in translating post- transplant cancer 
epidemiology between countries.
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epidemiology may not be translatable between countries 
with developed kidney transplantation programs such as 
England and the United States for a number of reasons. 
From a transplant perspective kidney allograft recipient 
phenotypes differ between England and the United States 
with regard to race, use of T- cell depletion as induction 
therapy and utilization of extended- criteria kidneys, all 
of which impact upon risk for cancer [12–14]. From a 
more generic perspective, England demonstrates signifi-
cantly less self- reported illnesses and biological markers 
of disease compared to the United States despite less than 
half the expenditure per person [15]. However, from a 
cancer perspective, England appears to have a lower inci-
dence but higher mortality from cancer compared to the 
United States [16]. Therefore, we can speculate that cancer- 
reported incidence and outcomes after kidney transplanta-
tion may not be translatable between countries in the 
context of significant imbalance in healthcare systems, 
patient demographics and nature of disease.
To investigate this further, and to determine whether 
country- specific cancer epidemiology post- transplantation is 
translatable between countries, we undertook a comparative 
population- cohort study between England and New York 
State (NYS) over a contemporaneous era. The aim was to 
ascertain if cancer- related epidemiology for kidney allograft 
recipients differ between the two countries to better inform 
clinical practice and guide targeted patient counseling.
Subjects­and­Methods
Study­population
We obtained data from every kidney- alone transplant pro-
cedure performed in England and New York State between 
2003 and 2013, collecting patient demographics that 
included age, gender, donor type (living or deceased), 
transplant year, medical comorbidities (based upon ICD- 10 
codes) and ethnicity. English data were obtained from 
Hospital Episode Statistics [17], an administrative data 
warehouse containing admissions to all National Health 
Service hospitals in England. It contains detailed records 
relating to individual patient treatments; with data extrac-
tion facilitated utilizing codes on procedural classifications 
(Office of Population Censuses and Surveys Classification 
of Interventions and Procedures, 4th revision [OPCS- 4]) 
[18] and medical classifications (World Health Organization 
International Classification of Disease, 10th revision [ICD- 
10]) [19]. The comparative analysis with the United States 
was performed with contemporaneous New York State data 
and extracted from the Statewide Planning and Research 
Cooperative System (SPARCS), a comprehensive all payer 
data reporting system collecting patient- level data across 
New York State [20]. The database collects information 
including patient demographics, diagnoses, procedures, and 
charges for every inpatient hospital admission, ambulatory 
surgical procedure, and emergency department admission. 
Individuals are assigned a unique, encrypted identification 
code, allowing for longitudinal analyses. Estimated report-
ing completeness obtained from SPARCS inpatient annual 
reports during the study period (2000- 11) ranged from 
95% to 100%, with an average of more than 98%.
This study included all kidney transplant procedures 
(OPCS- 4 codes; M01[0- 5,8,9]) performed in England and 
New York State between the years of 2003 to 2013. Cancer 
was defined as any post- transplant admission with ICD- 10 
codes C00- C96, while pretransplant cancer was diagnosed 
with appropriate ICD- 10 codes listed at time of kidney 
transplantation. With regard to outcome analysis, both 
HES and SPARCS data sets have the limitation of only 
capturing deaths occurring in a hospital setting. To obtain 
the complete mortality list, the study cohort was cross- 
referenced with mortality data from the Office for National 
Statistics and New York City/New York State vital statistics, 
respectively, which collects information on all registered 
deaths in the United Kingdom and New York State respec-
tively. Combining sources via this data linkage process 
creates a comprehensive dataset with regard to mortality, 
which was the endpoint of interest in this analysis. This 
study did not require institutional review board approval 
due to the pseudoanonymized nature of the data retrieved—
data were linked by NHS Informatics utilizing a special 
HES ID code and avoided patient identifiable codes. With 
regard to outcome analysis, both HES and SPARCS datasets 
have the limitation of only capturing deaths occurring in 
a hospital setting. To obtain the complete mortality list, 
the study cohort was cross- referenced with mortality data 
from the Office for National Statistics and New York 
State/New York City Vital Statistics respectively, which 
collects information on all registered deaths in the United 
Kingdom and New York State, respectively. Combining 
sources via this data linkage process creates a compre-
hensive dataset with regard to mortality, which was the 
endpoint of interest in this analysis. In addition, we 
extracted data for transplant rejection/failure (ICD- 10; 
T861 or ICD- 9; 99681). This study did not require insti-
tutional review board approval due to the pseudoan-
onymized nature of the data retrieved—data were linked 
by NHS Informatics utilizing a special HES ID code and 
avoided patient identifiable codes.
Data­inclusion
We extracted data on all kidney allograft recipients between 
the dates of 1st January 2003 and 31st December 2013, 
who underwent their kidney transplant procedure in a 
transplant center in either England or New York State. 
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We excluded the following patients from analysis; missing 
demographic data, combined solid- organ transplant, and 
pediatric cases (aged under 18 years).
Statistical­analysis
The primary outcome measures were cancer- related inci-
dence after kidney transplantation and the risk for mortality 
(including in- hospital death, 30- day and 1- year mortality) 
and kidney transplant failure.
Differences between groups were compared using chi- 
square tests for categorical variables and Mann–Whitney 
tests for all continuous variables. Survival analyses were 
performed, where time to event data was available, using 
Cox’s proportional hazards model and the generation of 
Kaplan–Meier plots. Otherwise multivariate logistic regres-
sion models were used. Variables included in the model 
were ethnicity, age, gender, donor type (living vs. deceased), 
year of transplant and selected medical comorbidities (his-
tory of myocardial infarction, peripheral vascular disease, 
cerebrovascular disease, congestive cardiac failure pulmo-
nary disease, liver disease, peptic ulcer, previous cancer 
and diabetes). Recipients were identified as having allograft 
failure if they fulfilled the above criteria and this was 
added as a covariate in the Cox model.
Missing data regarding area socio- economic deprivation 
were ascertained in only (0.6%) of the data and were 
adjusted for as dummy variables in the models as required 
(assuming not missing at random). Survival analyses were 
performed by generation of Kaplan–Meier curve estimates. 
A P < 0.05 was considered statistically significant in the 
analysis. Data were analyzed using Stata SE 14 (Stata 
Statistical Software: College Station, TX: Stata Corp LP).
Results
Between 2003 and 2013, there were 21,371 patients in England 
who had a kidney transplant recorded in Hospital Episode 
Statistics (HES). After excluding 2878 patients, due to miss-
ing demographic data and patients who had multi- organ 
transplants, we were left with 18,493 patients over the age 
of 18 for analysis. Over the same time span between 2003 
and 2013, there were 12,373 patients in NYS who had a 
kidney transplant recorded in the SPARCS. After excluding 
771 patients, due to missing demographic data and recipients 
of multi- organ transplants, we were left with 11,602 patients 
over the age of 18 for analysis. Median follow up after 
kidney transplantation in England and New York State was 
6.3 years and 5.5 years respectively. Total patient- years of 
follow up for kidney allograft recipients in England and 
NYS was 90,655 and 67,743, respectively.
Baseline­demographics
A comparison of baseline demographics between English 
and NYS kidney allograft recipients is given in Table 1. 
Table 1. Comparison of baseline demographics between England and New York State.
England (%) NYS (%)
P- valueTotal 18493 11602
Age Mean 47.61 50.88 <0.001
Post- transplant hospital stay Median 8 (6–13) 5 (4–7) <0.001
Sex Male 11370 (61.48%) 7033 (60.62%)
Female 7123 (38.52%) 4569 (39.38%) 0.136
Type of Donor Living 6706 (36.26%) 3977 (34.28%)
Deceased 11459 (61.96%) 5326 (45.91%)
Unknown 328 (1.77%) 2299 (19.82%) <0.001
Operation Year 2003 949 (5.13%) 835 (7.20%)
2004 1362 (7.36%) 957 (8.25%)
2005 1346 (7.28%) 1119 (9.64%)
2006 1471 (7.95%) 1226 (10.57%)
2007 1532 (8.28%) 1212 (10.45%)
2008 1763 (9.53%) 1174 (10.12%)
2009 1893 (10.24%) 1113 (9.59%)
2010 1938 (10.48%) 1034 (8.91%)
2011 1908 (10.32%) 1070 (9.22%)
2012 2038 (11.02%) 1041 (8.97%)
2013 2293 (12.40%) 821 (7.08%) <0.001
Pretransplant Cancer 1033 (5.59%) 408 (3.52%) <0.001
Ethnic Group White 14508 (78.45%) 6202 (53.46%)
Black 1215 (6.57%) 2660 (22.93%)
Other 2770 (14.98%) 2740 (23.62%) <0.001
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Significant differences were noted in baseline variables 
between the two cohorts, with the NYS cohort more likely 
to be older and non- White. Of interest, English kidney 
allograft recipients were more likely to have had pretrans-
plant cancer than NYS patients (5.6% vs. 3.5% respectively, 
P < 0.001).
Comparison­of­cancer­incidence­between­
England­and­NYS
English kidney allograft recipients were more likely to be 
admitted to hospital post- transplant with a new cancer 
diagnosis compared to NYS kidney allograft recipients. 
In total, 10.6% (n = 1965) of English recipients and 7.3% 
(n = 846) of NYS recipients were admitted with new 
development of cancer (P < 0.001). There was no dif-
ference in the median time to cancer diagnosis between 
England (3.7 years, IQR: 1.7–6.2) and NYS (3.5 years, 
IQR: 1.6–6.1) respectively (P = 0.288). Table 2 highlights 
the differences in cancer- specific incidence post kidney 
transplantation comparing England to NYS (Table S1. 
identifies cancer incidence within first year after kidney 
transplantation). The most notable difference between 
cohorts worthy of highlighting was significantly higher 
incidence of melanoma skin cancer in England versus 
NYS, which may reflect the lower frequency of non- Whites 
in the English kidney transplant cohort.
Comparison­of­all-­cause­mortality­and­
kidney­transplant­rejection/failure­between­
England­and­NYS
Kidney allograft recipients in England overall had lower 
all- cause mortality compared to their NYS counterparts 
at all time points investigated in this analysis; during the 
immediate postoperative stay (0.7% vs. 1.0% respectively, 
P = 0.011), after 30- days (0.9% vs. 1.8% respectively, 
P < 0.001) and after 1- year post kidney transplantation 
(3.0% vs. 5.1% respectively, P < 0.001). However, for 
kidney allograft recipients specifically who developed post- 
transplant cancer, there was no difference in 1- year mor-
tality between England versus NYS (2.6% vs. 3.4% 
respectively, P = 0.223). Too few in- hospital or 30- day 
deaths occurred for data to be released and analyzed for 
both English and NYS cohorts.
Kidney allograft recipients in England had lower risk 
for kidney transplant rejection/failure compared to their 
NYS counterparts. For kidney allograft recipients with 
post- transplant cancer, kidney transplant rejection/failure 
was less common in England versus NYS (26.9% vs. 69.0% 
respectively, P < 0.001) (see Fig. 1A). For kidney allograft 
recipients without post- transplant cancer, the risk for 
kidney transplant rejection/failure remained lower in 
England versus NYS (25.4% vs. 50.8% respectively) is 
shown in the unadjusted Kaplan–Meier plots (see Fig. 1B).
Adjusted­analysis
Table 3 highlights the multivariable logistic regression 
analysis looking at 1- year mortality after kidney trans-
plantation in both English and NYS cohorts after adjust-
ment for important covariables. It demonstrates patients 
admitted with cancer within the first year post- 
transplantation was a strong predictor for 1- year all- cause 
mortality in both England (Odds Ratio 5.0 [95% CI: 
3.6–6.9], P < 0.001) and NYS (Odds Ratio 3.3 [95% CI: 
2.0–5.6], P < 0.001). After incorporating all patients into 
a combined cohort, even after adjustment for cancer inci-
dence within the first year, kidney allograft recipients from 
NYS had increased odds for 1- year all- cause mortality 
compared to English counterparts (Odds Ratio 1.47 [95% 
CI: 1.29–1.67], P < 0.001).
We performed Cox regression analysis on kidney trans-
plant rejection/failure due to data availability regarding 
time to diagnosis. Regardless of whether the analysis focused 
on kidney allograft recipients with or without post- 
transplant cancer (Tables 4 and 5 respectively), kidney 
allograft recipients in NYS demonstrated higher hazard 
Table 2. Incidence of cancer comparing England versus New York State 
after kidney transplantation.
Post- transplant type of cancer England (%) NYS (%)
Lip, oral cavity and pharynx 33 (0.18) 16 (0.14)
Digestive organs 119 (0.64) 113 (0.97)
Respiratory and intrathoracic 
organs
73 (0.39) 108 (0.93)
Bone and articular cartilage 1 9 (0.08)
Melanoma and other malignant 
neoplasms of skin
848 (4.59) 53 (0.46)
Mesothelial and soft tissue 29 (0.16) 6 (0.05)
Breast 85 (0.46) 30 (0.26)
Female Genital Organs 37 (0.20) 21 (0.18)
Male Genital Organs 83 (0.45) 84 (0.72)
Kidney 113 (0.61) 97 (0.84)
Ureter 1 1
Bladder 51 (0.28) 28 (0.24)
Other and unspecified urinary 
organs
1 1
Eye, brain, and other parts of the 
central nervous system
11 (0.06) 9 (0.08)
Thyroid and other endocrine 
gland
16 (0.09) 19 (0.16)
Ill- defined, secondary, and 
unspecified sites
192 (1.04) 86 (0.74)
Lymphoid, hematopoietic, and 
related tissue
262 (1.42) 156 (1.34)
Independent multiple sites 1 1
1Numerically too few for data to be provided.
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ratios for development of kidney transplant rejection/failure 
compared to England.
Sensitivity analysis was conducted after excluding cancers 
that had occurred within the first 2 years’ post- transplant 
to exclude the possibility of reverse causality. Cancer inci-
dence rate (adjusted for age and sex) in England was 
90.6 versus 64.7 cases per 1000 patients for the whole 
cohort and after excluding cancers within the first 2 years, 
respectively. Cancer incidence rate (adjusted for age and 
sex) in NYS was 58.7 versus 39.9 cases per 1000 patients 
for the whole cohort and after excluding cancers within 
the first 2 years, respectively. Therefore, there was little 
difference in comparative incidence ratio for England 
versus NYS when comparing the whole cohort or early 
cancers excluded (1.54 [95% CI: 1.48–1.60] and 1.62 [95% 
CI: 1.55–1.69], respectively.
Discussion
To the best of our knowledge, this study is the first com-
parative analysis of cancer- related epidemiology after kidney 
transplantation between different countries. This 
population- cohort analysis, comparing kidney allograft 
recipients between England and NYS, suggests caution in 
extrapolating results between different patient cohorts but 
also raises some important topics for further 
discussion.
It is well recognized that kidney transplantation is asso-
ciated with an increased incidence of cancer compared 
to other stages of the renal disease spectrum [8], with 
comparable burden to other immune deficiency states such 
as HIV/AIDS [21]. Population- cohort analyses from dif-
ferent countries suggest similar post kidney transplantation 
risk for cancer regardless of geography. For example, Collett 
and colleagues explored cancer incidence after solid- organ 
transplantation in the United Kingdom by linking data 
between NHS Blood and Transplant to various cancer 
registries between 1980 and 2007 [11]. They demonstrated 
a twofold increased risk for incidence of post- transplant 
cancer compared to the general population and particularly 
high risk for nonmelanoma skin cancer [11]. This finding 
was surprisingly similar to the twofold increase in risk 
for cancer incidence identified in the United States popu-
lation by Kasiske and colleagues, who linked patients from 
the United States Renal Data System (USRDS) to Medicare 
billing claims to detect the occurrence of cancer [7].
However, disparate results have been published regarding 
the risk for cancer- related mortality between England and 
the United States. For the latter, Kiberd et al. identified 
1937 malignancy- related death amongst 164,078 first kidney 
allograft recipients recorded in the USRDS between January 
1990 and December 2004 [3]. They demonstrated no dif-
ference between the expected and observed cancer mortality 
rate, with equivalent standardized cancer mortality ratios 
with the general population, which the authors speculate 
could be attributed to the numerous competing risks for 
death that exist post- transplantation [3]. This contrasts 
with results from an English population- cohort study by 
Farrugia and colleagues, who identified cancer- related mor-
tality (as recorded by death certification) to be elevated 
for kidney allograft recipients in England (2001–2012 
cohort) compared to the general population after compet-
ing risk analysis [4]. It is important to identify numerous 
epidemiological differences between these population- 
cohort studies including disparate time periods, lack of 
comparable baseline demographics and different transplant 
practice. However, subsequent publications from Canada 
support the findings from Farrugia and colleagues linking 
increased cancer- related mortality for kidney allograft 
recipients [5]. Our study lacked cancer- specific mortality 
data, which is a limitation, but all- cause mortality rates 
for kidney allograft recipients was lower in England versus 
Figure 1. Kaplan–Meier plot of time to kidney transplant rejection/failure for kidney allograft recipients with or without post- transplant cancer in 
England versus New York State.
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NYS. This is consistent with data demonstrating superior 
long- term outcomes after kidney transplantation in Europe 
compared to the United States; for example, Ojo and 
colleagues found kidney allograft recipients in the United 
States had more than double the long- term hazard for 
death with graft function (regardless of whether cause of 
end- stage kidney disease was diabetes or not) [22].
While all- cause mortality was significantly lower for 
English versus NYS kidney allograft recipients in our analy-
sis, we did not identify any increased risk for death post- 
transplantation among those who developed cancer. 
Epidemiological studies of the general population have 
consistently given the interpretation of superior cancer 
survival in the United States compared to countries like 
the United Kingdom, based upon studies looking at global 
cancer incidence and mortality [8]. For example, the world-
wide population- based study entitled CONCORD high-
lighted superior 5- year survival rates for prostate cancer 
patients diagnosed in the United States (91.9%) compared 
to the United Kingdom (51.1%) [23]. However, such crude 
interpretations of the raw data belie a more complicated 
scenario. For example, the use of prostate hormone antigen 
(PSA) has been more prevalent in the United States com-
pared to places like Europe. This results in better detection 
of prostate cancer in the United States, and subsequently 
one of the highest recorded rates of prostate cancer, but 
inevitably labels some men with prostate cancer who will 
never die from the disease. Recent studies have cast doubt 
on the ubiquitous use of PSA [24, 25] and published 
recommendations against the routine use of PSA [26] have 
led to subsequent falls of PSA testing in the United States 
[27]. The efficacy of cancer screening from a transplanta-
tion perspective remains even more unproven than the 
Table 3. Logistic regression analysis of 12- month mortality in England 
versus New York State with cancer diagnosis within first year.
Variable Odds Ratio (95% CI) P- value
England
Age <50 1 (baseline group)
50+ 3.76 (3.07,4.61) <0.001
Sex Male 1 (baseline group)
Female 1.06 (0.89,1.27) 0.495
Ethnicity Black 1 (baseline group)
Other 1.27 (0.85,1.90) 0.234
White 0.94 (0.65,1.34) 0.728
Number of 
readmissions
0 1 (baseline group)
1 to 3 0.70 (0.56,0.86) 0.001
3 + 0.42 (0.34,0.52) <0.001
Cancer within 
1 year after
Yes 5.01 (3.64,6.90) <0.001
No 1 (baseline group)
New York State
Age <50 1 (baseline group)
50+ 1.44 (1.21,1.72) <0.001
Sex Male 1 (baseline group)
Female 1.05 (0.89,1.25) 0.762
Ethnicity Black 1 (baseline group)
Other 0.74 (0.59,0.94) 0.064
White 0.67 (0.55,0.82) <0.001
Number of 
readmissions
0 1 (baseline group)
1 to 3 0.89 (0.73,1.09) 0.261
3 + 0.46 (0.37,0.58) <0.001
Cancer within 
1 year after
Yes 3.33 (1.99,5.57) <0.001
No 1 (baseline group)
Table 4. Cox regression analysis of kidney transplant rejection/failure 
for noncancer patients.
Hazard Ratio (95% CI) P- value
Age <50 1 (baseline group)
50 + 0.87 (0.84,0.91) <0.001
Sex Male 1 (baseline group)
Female 1.04 (0.99,1.08) 0.096
Ethnic Group White 1 (baseline group)
Black 0.75 (0.70,0.80) <0.001
Other 0.84 (0.79,0.89) <0.001
Type of Donor Alive 1 (baseline group)
Dead 1.33 (1.27,1.39) <0.001
Unknown 0.99 (0.92,1.07) 0.86
Diabetes 1.12 (1.06,1.17) <0.001
Acute MI 1.05 (0.98,1.13) 0.19
CVF 1.11 (1.02,1.20) 0.016
PVD 1.16 (1.07,1.25) <0.001
CHF 1.12 (1.05,1.19) <0.001
Year Pre 2007 1 (baseline group)
Post 2007 1.20 (1.14,1.26) <0.001
Country England 1 (baseline group)
NYS 2.20 (2.10,2.30) <0.001
Table 5. Cox regression analysis of kidney transplant rejection/failure 
for cancer patients.
Hazard Ratio  
(95% CI)
P- value
Age <50 1 (baseline group)
50 + 0.87 (0.76,1.00) 0.044
Sex Male 1 (baseline group)
Female 0.93 (0.82,1.06) 0.288
Ethnic Group White 1 (baseline group)
Black 0.92 (0.73,1.17) 0.506
Other 0.92 (0.76,1.11) 0.365
Type of Donor Alive 1 (baseline group)
Dead 1.08 (0.94,1.24) 0.287
Unknown 0.85 (0.69,1.04) 0.119
Diabetes 1.21 (1.06,1.39) 0.007
Acute MI 0.93 (0.76,1.15) 0.523
CVF 1.11 (0.87,1.41) 0.403
PVD 1.08 (0.86,1.35) 0.497
CHF 1.06 (0.88,1.27) 0.561
Year Pre 2007 1 (baseline group)
Post 2007 1.52 (1.33,1.74) <0.001
Country England 1 (baseline group)
NYS 3.16 (2.74,3.65) <0.001
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general population [28]. More recent data from the 
CONCORD- 2 study continues to show wide differences 
in cancer- linked survival globally that are attributed to 
differences in access to early diagnosis and optimum treat-
ment [29]. Considering kidney allograft recipients remain 
under close monitoring under the care of transplant neph-
rologists, we can speculate that such lifelong surveillance 
confounds any major difference for a transplant cohort. 
Our observation of no difference in all- cause mortality 
for kidney allograft recipients with post- transplant cancer 
(in contrast to the overall kidney allograft recipient cohort) 
hints at differential care for this select cohort of patients 
in NYS but this requires further analysis of patient- level 
data at a more granular basis before drawing any firm 
conclusions. However, attempting to explain difference in 
outcomes for our cohorts, which is likely secondary to 
multi- factorial reasons, is beyond the scope of this pub-
lication and would be too crude with the current dataset 
for definitive investigation. Differences in health care fund-
ing, services and delivery likely all confound a formal 
comparison of cohorts between England and NYS. For 
example, studies comparing healthcare systems in the United 
Kingdom with elsewhere, including the United States, have 
shown differences in expenditure (lower in England) [30] 
and cost effectiveness (lower in United States) [31]. 
However, it should be noted that cancer- related mortality 
has been reducing over the last 10–15 years in both England 
and the United States [32, 33] and our differences in 
outcome must be interpreted against this background.
English kidney allograft recipients admitted for trans-
plantation were more likely to have a pretransplant diag-
nosis for cancer in our analysis, which may be linked 
to the increased incidence of post- transplant cancer seen 
in England post- transplantation (although we lacked data 
to show if this was recurrent or new onset cancer). 
Facilitating kidney transplantation for more patients with 
previous cancer may be the most appropriate clinical 
course of action. For example, Viecelli and colleagues 
analyzed the Australian and New Zealand Dialysis and 
Transplant Registry, which highlighted recurrent and sec-
ond primary cancers were infrequent after kidney trans-
plantation among patients with a previous history of 
cancer [34]. In addition, a history of pretransplant cancer 
did not have an additive effect on the cancer- specific 
and overall survival of kidney transplant recipients who 
developed post- transplant cancer [34]. However, this 
contrasts sharply with findings from Farrugia and col-
leagues who demonstrated pretransplant cancer in an 
English kidney transplant cohort had the strongest hazard 
for post- transplant cancer- related mortality (Hazard Ratio 
7.653, 95% confidence interval 4.231–13.844, P < 0.001) 
[4]. This discordance again highlights the difficulty in 
translating data between different kidney transplant 
cohorts and the need for more global epidemiological 
comparisons of post- transplant complications (like cancer) 
to improve our understanding.
This study has several limitations which must be acknowl-
edged for both accurate interpretations of our data and 
to ensure targeted opportunities for further clinical research. 
Epidemiological studies such as these are reliant upon 
extraction of data from regional or national registries, 
which come with the usual caveats attributable to the 
accuracy and completeness of registry data. We are also 
being presumptive that NYS data is reflective of the wider 
population of the United States, which may not be accu-
rate from both a demographic and transplant practice 
perspective, and our data should be interpreted specifically 
as a comparison of data between England and NYS. While 
data linkage allowed us to extract all- cause mortality for 
all our patients, we were unable to obtain cause of death. 
This would be important to ascertain the rates of cancer- 
related and non- cancer- related mortality after a diagnosis 
of post- transplant cancer is made and how this differs 
from the general population. In addition, we relied about 
coding diagnoses for kidney transplant rejection/failure 
due to the inability to link our data to the specific UK- 
or US- based Transplant Registries, which would have made 
our kidney transplant outcomes more robust. Similar 
limitations exist for extracting cancer data from admin-
istrative registries, which has recently been shown to be 
inferior to dedicated cancer registries in the United States 
[35]. There are lots of biases to make a direct comparison 
difficult to interpret (e.g., ethnicity, recipient age, donor 
profiles). Finally, we lacked more granular patient- level 
data on important variables including smoking status, 
immunosuppression, pretransplant cancer histology etc. 
The ability to extract more data, and to link datasets to 
create more comprehensive databases, will allow the mini-
mization of confounding and hopefully can provide a 
strong platform from which to conduct meaningful post- 
transplant epidemiological analyses to guide clinical man-
agement and patient counseling. This is especially important 
with regard to immunosuppression, which is one of the 
major modifiable risk factors for the development of cancer 
after kidney transplantation.
To conclude, our contemporaneous comparison of kid-
ney allograft recipients between England and New York 
State demonstrates significant differences relating to cancer- 
linked epidemiology at both baseline demographics and 
post- transplant outcomes between the two cohorts. Our 
analysis suggests caution in translating data between coun-
tries and the need for more global epidemiological studies 
to ascertain aspects of care that differ between countries. 
However, this work does not attempt to tackle the under-
lying reasons for these differences, which is the subject 
of ongoing work. Further work focusing on these 
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differences in surveillance, diagnosis and management of 
cancer after transplantation is critical to develop consensus 
opinion concerning best practice. By doing so, we can 
aim to optimize the risk attenuation and clinical manage-
ment of cancer for kidney allograft recipients globally 
and ultimately work towards prolonging both patient and 
kidney allograft survival.
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